About Meridian Bioscience Inc.
Meridian Bioscience provides best-in-class diagnostic platforms, tests, education, and support to help you deliver answers.
Meridian Bioscience Inc. news and updates
Meridian Bioscience, Inc. hired Baldasare as CFO on Jan 1st 00'.
Mr. Baldasare joined Meridian in 2000 and has served as CFO since July 2019.
Jan 1, 2021 | biospace.comMeridian Bioscience, Inc. hired Phillips as board chair on Jan 1st 00'.
Phillips joined Meridian's board in 2000 and served as board chair since 2018.
Jan 1, 2022 | bizjournals.comMeridian Bioscience, Inc. hired David Phillips as chairman of the board on Sep 20th 18'.
Meridian has appointed David Phillips as the new chairman of the board, and has also elected Felicia Williams to the board of directors and to serve on the firm's audit committee, effective September 20, 2018.
Jan 1, 2018 | genomeweb.comMeridian Bioscience, Inc. hires Anthony Bihl III as Board of Directors
Meridian Bioscience, Inc. (NASDAQ: VIVO) announces the appointment of Anthony Bihl III to its Board of Directors, effective immediately.
Jan 1, 2020 | meridianbioscience.comMeridian Bioscience, Inc. hired John McIlwraith as Chairman of the Meridian Board of Directors on Jan 26th 22'.
Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that John C. McIlwraith has been elected as Chairman of the Meridian Board of Directors, effective January 26, 2022.
Jan 1, 2022 | instrumentbusinessoutlook.comMeridian Bioscience, Inc. hired Andy Kitzmiller as Executive Vice President and Chief Financial Officer on Feb 21st 22'.
Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that Andy Kitzmiller joined Meridian Bioscience as Executive Vice President and Chief Financial Officer, reporting directly to CEO Jack Kenny.
Jan 1, 2022 | wfmz.comJohn (Jack) A. Kraeutler retired from Meridian Bioscience, Inc. as Executive Chairman of the Board on Sep 30th 18'.
Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced that John (Jack) A. Kraeutler, Executive Chairman of the Board, will retire effective September 30, 2018.
Jan 1, 2018 | ptcommunity.comBryan Baldasare retired from Meridian Bioscience, Inc. as Executive Vice President, Chief Financial Officer, and Secretary on Dec 31st 21'.
Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that Bryan Baldasare, Executive Vice President, Chief Financial Officer, and Secretary, will retire from Meridian effective December 31, 2021.
Jan 1, 2021 | biospace.comGlenmede Investment Management LP invests into Meridian Bioscience, Inc.
Pennsylvania-based Glenmede Na has invested 0% in Meridian Bioscience, Inc. (NASDAQ:VIVO).
Jan 1, 2019 | makdaily.comVerityinvest invests into Meridian Bioscience, Inc.
North Carolina-based Verity Asset Management Inc has invested 0.39% in Meridian Bioscience, Inc. (NASDAQ:VIVO).
Jan 1, 2018 | mmahotstuff.comMeridian Bioscience, Inc. acquires Bioline Limited
In2grate were awarded the contract to undertake the implementation after Meridian Biosciences acquired Bioline which is UK based.
Jan 1, 2017 | benzinga.comMeridian Bioscience, Inc. acquired Genepoc for $120M on Jun 3rd 19'.
Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced it has completed its previously announced acquisition of the business of GenePOC Inc., a Quebec City, Quebec, Canada based provider of molecular diagnostic instruments and assays.
Jan 1, 2019 | globenewswire.comMeridian Bioscience, Inc. acquired Exalenz Bioscience Ltd. for $49M on Feb 19th 20'.
Meridian Bioscience, Inc. (NASDAQ: VIVO) and Exalenz Bioscience Ltd. (TASE: EXEN) announced today that the two companies have entered into a definitive agreement for Meridian to acquire Exalenz for ₪6.10 per share in cash with an implied transaction value of approximately $49 million.
Jan 1, 2020 | meridianbioscience.comMetropolitan Life Ltd. invests into Meridian Bioscience, Inc.
New York-based Metropolitan Life has invested 0.01% in Meridian Bioscience, Inc. (NASDAQ:VIVO).
Jan 1, 2019 | enherald.comTeton Advisors, Inc. invests into Meridian Bioscience, Inc.
Teton Advisors Inc has invested 0.18% of its portfolio in Meridian Bioscience, Inc. (NASDAQ:VIVO).
Jan 1, 2019 | livesadvice.comAmeriprise Financial, Inc. invests into Meridian Bioscience, Inc.
Ameriprise has invested 0% in Meridian Bioscience, Inc. (NASDAQ:VIVO).
Jan 1, 2019 | yomiblog.comCredit Suisse Group invests into Meridian Bioscience, Inc.
Credit Suisse Ag invested 0% of its portfolio in Meridian Bioscience, Inc. (NASDAQ:VIVO).
Jan 1, 2019 | dminute.comJobs Ohio invested into Meridian Bioscience, Inc. in $5.5M on Feb 3rd 21'.
Meridian Bioscience said on Wednesday that it has received $5.5 million from the National Institute of Health's Rapid Acceleration of Diagnostics initiative, along with a grant of undisclosed size from JobsOhio, to expand production capacity of its SARS-CoV-2 PCR test.
Jan 1, 2021 | genomeweb.comSeic invests into Meridian Bioscience, Inc.
Sei has invested 0% in Meridian Bioscience, Inc. (NASDAQ:VIVO).
Jan 1, 2019 | stocksbeat.comAzasrs invests into Meridian Bioscience, Inc.
Arizona State Retirement System has invested 0.01% in Meridian Bioscience, Inc. (NASDAQ:VIVO).
Jan 1, 2018 | cardinalweekly.comMeridian Bioscience, Inc. promoted Eric Rasmussen on Jan 1st 19'.
Meridian also promoted Eric Rasmussen from his role as EVP of corporate development to the position of EVP, CFO, and principal financial officer, also effective Jan. 1, 2019.
Jan 1, 2018 | 360dx.comMeridian Bioscience, Inc. promotes Tony Serafini-Lamanna to Executive Vice President of Diagnostics
Meridian Bioscience, Inc.’s (NASDAQ: VIVO) Board of Directors announced that Tony Serafini-Lamanna has been promoted to Executive Vice President of Diagnostics.
Jan 1, 2020 | globenewswire.comMeridian Bioscience, Inc. received financing of $1M in funding on Dec 16th 20'.
Meridian Bioscience said on Wednesday that it has received approximately $1 million in funding from the National Institute of Health's Rapid Acceleration of Diagnostics program to expedite the launch of its SARS-CoV-2 PCR test.
Jan 1, 2020 | genomeweb.comMenta Limited Co invests into Meridian Bioscience, Inc.
Menta Limited has invested 0.08% of its portfolio in Meridian Bioscience, Inc. (NASDAQ:VIVO).
Jan 1, 2019 | makdaily.comSwiss Bank In Your Pocket invests into Meridian Bioscience, Inc.
Swiss Bank has invested 0% in Meridian Bioscience, Inc. (NASDAQ:VIVO).
Jan 1, 2019 | finreviewer.comPiedmont Advisors invests into Meridian Bioscience, Inc.
North Carolina-based Piedmont Advisors has invested 0.01% in Meridian Bioscience, Inc. (NASDAQ:VIVO).
Jan 1, 2019 | makdaily.comMeridian Bioscience, Inc. recognized as Emergency Use Authorization
Meridian Bioscience Inc. said that its Revogene SARS-CoV-2 assay was granted Emergency Use Authorization by the U.S. Food and Drug Administration.
Jan 1, 2021 | marketwatch.comMeridian Bioscience, Inc. received award Emergency Use Authorization on Nov 10th 21'.
Meridian Bioscience announced on Wednesday that its Revogene SARS-CoV-2 test has received Emergency Use Authorization from the US Food and Drug Administration.
Jan 1, 2021 | genomeweb.comMeridian Bioscience, Inc. partners with U.S. Food and Drug Administration
Meridian Bioscience, Inc.'s subsidiary, Magellan Diagnostics, Inc., is currently working with the U.S. Food and Drug Administration (FDA) regarding use of venous blood (blood drawn from a vein) with its LeadCare Testing Systems.
Jan 1, 2017 | nasdaq.comMeridian Bioscience, Inc. partners with QuantuMDx Group Limited
Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading provider of diagnostic testing solutions and life science raw materials, is pleased to announce its collaboration with QuantuMDx on its newly launched SARS-CoV-2 assay for laboratory use.
Jan 1, 2020 | globenewswire.comMeridian Bioscience, Inc. partners with Syntron Bioresearch, Inc.
Per the fiscal second-quarter earnings call, Meridian Bioscience collaborated with Syntron Bioresearch to distribute their QuickPac II coronavirus test.
Jan 1, 2020 | yahoo.comREDI Cincinnati partners with Meridian Bioscience, Inc.
Meridian Bioscience is one of 27 projects that have moved to Phase 2, with a focus on scaling manufacturing to increase the capacity of testing in the U.S. JobsOhio and REDI Cincinnati are partnering with Meridian to support its growth on the Meridian Bioscience campus in Newtown, Ohio.
Jan 1, 2021 | globenewswire.comMeridian Bioscience, Inc. launched TRUBlock Ultra on Sep 1st 17'.
For instance,in September 2017, Meridian Life science Inc. launched TRUBlock Ultra, which is an active immunoassay interference blocker used for the detection of rheumatoid factor (RH), and heterophillic antibodies (HA).
Jan 1, 2020 | openpr.comMeridian Bioscience, Inc. launched novel highly sensitive SARS-CoV-2 antibody pair to the trimeric spike protein to accelerate development of COVID-19 assays from patient saliva on Sep 14th 20'.
Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading provider of diagnostic testing solutions and life science critical raw materials, is pleased to announce the launch of a novel highly sensitive SARS-CoV-2 antibody pair to the trimeric spike protein to accelerate development of COVID-19 assays from patient saliva.
Jan 1, 2020 | globenewswire.comMeridian Bioscience, Inc. launched TruQuick on Feb 3rd 17'.
Meridian Bioscience has launched TruQuick, a comprehensive point-of-care product menu of rapid tests for the diagnosis of tropical, infectious, sexually transmitted, respiratory, gastrointestinal, cancer, and cardiac diseases.
Jan 1, 2017 | genomeweb.comMeridian Bioscience, Inc. launched TRUBlock Ultra on Sep 1st 17'.
For instance, in September 2017, Meridian Life science Inc. launched TRUBlock Ultra, which is an active immunoassay interference blocker used for the detection of rheumatoid factor (RH), and heterophillic antibodies (HA).
Jan 1, 2018 | marketresearchtime.comMeridian Bioscience, Inc. launched ImmunoCard STAT product line by addition of Immuno Card STAT FLU A&B on Jan 1st 17'.
For instance, in 2017, Meridian Bioscience, Inc(U.S.) expanded its ImmunoCard STAT product line by addition of Immuno Card STAT FLU A&B which detects the presence of influenza A & B in nasal and nasopharyngeal swabs.
Jan 1, 2019 | marketanalyst24.comMeridian Bioscience, Inc. launched High-Specificity Pfu HS Mix on Jan 23rd 20'.
Cincinnati, OH (GLOBE NEWSWIRE) - Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced the launch of a High-Specificity Pfu HS Mix that not only provides high-fidelity amplification, but also offers market-leading amplification for companion diagnostic (CDx) and clinical testing.
Jan 1, 2020 | laboratorynetwork.comMeridian Bioscience, Inc. launched Inhibitor-tolerant qPCR Mix on Apr 18th 19'.
Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced the launch of its Inhibitor-tolerant qPCR Mix, a novel mix to accelerate workflows and improve DNA target amplification and quantification from crude samples; adding to its growing portfolio of molecular diagnostic products.
Jan 1, 2019 | globenewswire.comMeridian Bioscience, Inc. launched Air-Dryable RT-qPCR Mix on Dec 3rd 20'.
Meridian Bioscience, Inc. (NASDAQ: VIVO ), a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of its new Air-Dryable ™ Direct RNA/DNA qPCR Blood Mix.
Jan 1, 2020 | streetinsider.comMeridian Bioscience, Inc. launched novel SARS-CoV-2 antibody pair on Sep 14th 20'.
Press Release reported on 09/14/20 that Meridian launches a novel SARS-CoV-2 antibody pair designed for developing highly sensitive rapid antigen tests from saliva samples Is It Worth Investing in Meridian Bioscience Inc. (NASDAQ :VIVO) Right Now?
Jan 1, 2020 | newsheater.comMeridian Bioscience, Inc. launched Emergency Use Authorization application update on Feb 16th 21'.
On February 16, 2021, Meridian issued a press release "provid[ing] an update on its application for Emergency Use Authorization (EUA) with the U.S. Food and Drug Administration (FDA) for the SARS-CoV-2 molecular diagnostic test on its Revogene ® platform."
Jan 1, 2021 | prnewswire.comMeridian Bioscience, Inc. launched series of recombinant antigens for high sensitivity and specificity IgG/IgM COVID-19 antibody tests on Apr 14th 20'.
To meet the massive need for antibody testing, Meridian has now launched a series of recombinant antigens for high sensitivity and specificity IgG/IgM COVID-19 antibody tests.
Jan 1, 2020 | globenewswire.comMeridian Bioscience, Inc. launched Air-Dryable Direct RNA/DNA qPCR Blood Mix on Oct 7th 21'.
Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of its new Air-Dryable ™ Direct RNA/DNA qPCR Blood Mix.
Jan 1, 2021 | marketscreener.comMeridian Bioscience, Inc. launched Lyo-Ready DNA LAMP Mix on Apr 28th 21'.
Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of the Lyo-Ready™ DNA LAMP Mix, specifically designed for accelerating the development of ambient temperature-stable loop-mediated isothermal amplification (LAMP) assays.
Jan 1, 2021 | biospace.comMeridian Bioscience, Inc. increases headcount by 45
“Meridian has been a valued, long-term resident of Newtown for over 40 years and is once again expanding their presence through economic investment and the addition of 45 full-time jobs.
Jan 1, 2021 | indianconventions.comMeridian Bioscience, Inc. expands facilities to Quebec City, Canada
Meridian will also expand production at its facility in Quebec City.
Jan 1, 2021 | bizjournals.comNasdaq, Inc filed suit against Meridian Bioscience, Inc. on Dec 11th 17'.
San Diego, CA -- ( SBWIRE ) -- 12/11/2017 -- An investor, who purchased NASDAQ:VIVO shares, filed a lawsuit against Meridian Bioscience, Inc. over alleged violations of Federal Securities Laws.
Jan 1, 2017 | digitaljournal.comMeridian Bioscience, Inc. has issues with potential breach of fiduciary duty claim
Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Meridian Bioscience, Inc. (NASDAQ: VIVO).
Jan 1, 2020 | yahoo.comMeridian Bioscience, Inc. has issues with securities fraud or other unlawful business practices
The investigation concerns whether Meridian and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
Jan 1, 2017 | prnewswire.comMeridian Bioscience, Inc. had issues with possible violations of federal securities laws on Nov 8th 17'.
Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a boutique securities firm headquartered at the Empire State Building in New York City announces an investigation against Meridian Bioscience, Inc. (NASDAQ: VIVO)("Meridian" or the "Company") for possible violations of federal securities laws.
Jan 1, 2017 | businessinsider.comMeridian Bioscience, Inc. had issues with potential violations of the federal securities laws on Feb 23rd 21'.
BOSTON, MA / ACCESSWIRE / February 23, 2021 / Block & Leviton LLP ( www.blockleviton.com ), a national securities litigation firm, announces that it is investigating Meridian Bioscience, Inc. (NASDAQ:VIVO) for potential violations of the federal securities laws.
Jan 1, 2021 | yahoo.comMeridian Bioscience, Inc. is developing Revogene diagnostic platform
Unrelated to COVID-19, Meridian is "working on a proprietary panel on its Revogene diagnostic platform, which does away with the need to RNA extraction," Chen indicated.
Jan 1, 2020 | investorideas.comMeridian Bioscience, Inc. launched two new innovative master mixes, Lyo-Ready Direct DNA LAMP Saliva Mix and Lyo-Ready Direct RNA/DNA LAMP Saliva Mix on May 17th 22'.
Meridian Bioscience, Inc. (NASDAQ: VIVO ), a leading global provider of diagnostic testing solutions and life science raw materials, announced today the continued expansion of its isothermal amplification product line with the launch of two new innovative master mixes, Lyo-Ready™ Direct DNA LAMP Saliva Mix and Lyo-Ready™ Direct RNA/DNA LAMP Saliva Mix.
Jan 1, 2022 | streetinsider.comMeridian Bioscience, Inc. has issues with COVID-19 antigen testing
Meridian ( VIVO ) has benefitted from a strong demand for reagents associated with COVID-19 antigen testing, particularly during the recent Omicron wave.
Jan 1, 2022 | seekingalpha.comSD Biosensor, Inc acquired Meridian Bioscience, Inc. for $1.53B on Jul 7th 22'.
:Meridian Bioscience Inc will be acquired by SD Biosensor Inc and PE firm SJL Partners LLC in an all-cash US$1.53-billion deal, the companies said on Thursday, accelerating the South Korean diagnostic firm's entry into the U.S. market.
Jan 1, 2022 | todayonline.comSJL Partners LLC acquires Meridian Bioscience, Inc. for $1.53B
South Korean billionaire Cho Young-sik's SD Biosensor and Seoul-based private equity firm SJL Partners said they are acquiring Nasdaq-listed diagnostics company Meridian Bioscience for $1.53 billion in cash, paving the way for SD Biosensor's entry into the huge U.S. market.
Jan 1, 2022 | latestnigeriannews.comMeridian Bioscience, Inc. launched Revogene SARS-CoV-2 assay on Nov 10th 21'.
On November 10, 2021, Meridian announced the Revogene ® SARS-CoV-2 assay was grant ed authorization by the FDA.
Jan 1, 2022 | cmocro.com